Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 05/22/17

NCI Experimental Therapeutics
Clinical Trials Network (ETCTN)

Overview/Objectives

The National Cancer Institute (NCI) has formed partnerships in the pharmaceutical industry, academic institutions, and individual investigators for the early clinical evaluation of innovative cancer therapies. The Experimental Therapeutics Clinical Trials Network (ETCTN) was created to evaluate these therapies using a coordinated, collaborative, and inclusive team-based approach to early phase experimental therapeutic clinical trials.

The objectives of the ETCTN are to:

  • Conduct early clinical trials of NCI-IND agents in high priority areas of unmet medical needs
  • Ensure efficient and timely activation and conduct of these clinical trials
  • Integrate preclinical findings using clinical samples for biomarker analysis
  • Promote collaboration among institutions and investigators
  • Integrate molecular characterization, pharmacology, cancer biology, and imaging into clinical trials

See the links in the sidebar for more information about the ETCTN.

ETCTN Participating Sites

ETCTN Phase 1 and Phase 2 Program Sites

ETCTN clinical sites (see map above) participate in a Phase 1 Program supported by UM1 grants, integrated with a Phase 2 Program supported by cooperative agreements as supplements to the existing phase 1 UM1 grant. By integrating Phase 1 and Phase 2 Program activities and administrative operations under the UM1 structure, ETCTN awardees will have the flexibility to expand phase 1 studies quickly upon detecting early activity signals.

LAO Organization
University Health Network Princess Margaret Cancer Center LAO*
University Health Network-Princess Margaret Hospital
BCCA-Vancouver Cancer Centre
BCCA-Vancouver Island Cancer Centre
BCCA-Fraser Valley Cancer Centre
BCCA-Cancer Centre for the Southern Interior
BCCA-Abbotsford Cancer Centre
BCCA-Cancer Centre for the North
Moffitt Cancer Center
Moffitt Cancer Center-International Plaza
City of Hope Comprehensive Cancer Center LAO
City of Hope Comprehensive Cancer Center
City of Hope South Pasadena
City of Hope Antelope Valley
USC / Norris Comprehensive Cancer Center
Los Angeles County-USC Medical Center
Keck Medical Center of USC Pasadena
Stanford Cancer Institute
University of California Davis Comprehensive Cancer Center
Yale University Cancer Center LAO
Yale University
Smilow Cancer Center/Yale-New Haven Hospital
Wayne State University/Karmanos Cancer Institute
Vanderbilt University/Ingram Cancer Center
UC San Diego Moores Cancer Center
University of California San Diego
UCSF Medical Center-Mission Bay
UCSF Medical Center-Parnassus
UCSF Medical Center-Mount Zion
Translational Genomics Research Institute
Dana-Farber - Harvard Cancer Center LAO
Dana-Farber/Harvard Cancer Center
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Massachusetts General Hospital Cancer Center
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Johns Hopkins University/Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Suburban Hospital
Johns Hopkins Bayview Medical Center
MedStar Georgetown University Hospital
Emory University/Winship Cancer Institute
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University Hospital
University of Virginia Cancer Center
Mayo Clinic Cancer Center LAO
Mayo Clinic
Mayo Clinic in Arizona
Mayo Clinic Hospital
Mayo Clinic in Florida
University of Maryland/Greenebaum Cancer Center
University of Iowa/Holden Comprehensive Cancer Center
Columbia University/Herbert Irving Cancer Center
National Cancer Institute LAO
National Cancer Institute Developmental Therapeutics Clinic
National Institutes of Health Clinical Center
NCI Center for Cancer Research
Duke University - Duke Cancer Institute LAO
Duke University Medical Center
Washington University School of Medicine
Barnes-Jewish Hospital
Barnes-Jewish West County Hospital
Siteman Cancer Center-South County
UNC Lineberger Comprehensive Cancer Center
Rutgers University - Cancer Institute of New Jersey LAO
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
University of Wisconsin Hospital and Clinics
Ohio State University Comprehensive Cancer Center LAO
Ohio State University Comprehensive Cancer Center
JamesCare at Ohio State University Hospital East
Stefanie Spielman Comprehensive Breast Center
JamesCare Gynecologic Oncology at Mill Run
Case Western Reserve University
Cleveland Clinic Foundation
University of Kentucky/Markey Cancer Center
University of Pittsburgh Cancer Institute LAO
University of Pittsburgh Cancer Institute (UPCI)
UPMC-Montefiore Hospital
University of Pennsylvania/Abramson Cancer Center
University of Texas MD Anderson Cancer Center LAO
M D Anderson Cancer Center
University of Colorado Cancer Center - Anschutz Cancer Pavilion

*LAO = Lead Academic Organization

NCI Early Drug Development Opportunity Program (EDDOP)

Beginning in 2016, investigators from certain NCI-designated Cancer Centers not affiliated with the ETCTN may submit a Letter of Intent (LOI) and, if approved, receive full ETCTN support for the clinical trial. Non-ETCTN NCI Cancer Centers will also be able to compete for administrative supplements to enroll patients on select ETCTN phase 2 trials. Click here for more information about the EDDOP.

Other ETCTN-affiliated Networks

Other consortia which participate in ETCTN trials are:

NCI-sponsored Infrastructure for ETCTN Trials

ETCTN trials are supported by integrated centralized clinical and administrative services sponsored by NCI. More details, and links to each service, may be found here.

ETCTN Trials by Disease

ETCTN studies are listed by disease category and include trials that are currently in review, approved, and active.